OncoImmunology · 2014 · 95 citations · 10 references
MedicineCancer BiologyOncologyCancer PharmacologyChemotherapyMolecular OncologyCancer ImmunotherapyCytokine BiologyCytokines In Tumor ImmunityHematologic Malignancy TherapyLymphoid NeoplasmsMultiple MyelomaE3 Ubiquitin Ligase Substrate RecognitionInterleukin Pathway InhibitionLenalidomide TherapyMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentMyeloma PathogenesisRegulation By E3 Ubiquitin Ligases
Lenalidomide and its analogs, thalidomide and pomalidomide, specifically inhibit growth of mature B-cell lymphomas, including multiple myeloma, and induce interleukin-2 (IL-2) release from T cells. We recently found that this results from activation of the CRBN-CRL4 E3 ubiquitin ligase to degrade the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos).
10
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science · 2010 · 2.1K citations
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Krönke, Namrata D. Udeshi, Anupama Narla et al. · Science · 2013 · 1.8K citations · Full text
Medicine, Cell Biology, Oncology +14
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Charles G. Mullighan, Salil Goorha, Ina Radtke et al. · Nature · 2007 · 1.8K citations
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Xu Tan, Luz Irina A. Calderón Villalobos, Michal Sharon et al. · Nature · 2007 · 1.7K citations
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu, Richard E. Middleton, Huahang Sun et al. · Science · 2013 · 1.6K citations · Full text